NZ701469A - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators - Google Patents
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorsInfo
- Publication number
- NZ701469A NZ701469A NZ701469A NZ70146913A NZ701469A NZ 701469 A NZ701469 A NZ 701469A NZ 701469 A NZ701469 A NZ 701469A NZ 70146913 A NZ70146913 A NZ 70146913A NZ 701469 A NZ701469 A NZ 701469A
- Authority
- NZ
- New Zealand
- Prior art keywords
- glucocorticoid receptor
- heteroaryl
- receptor modulators
- fused azadecalin
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651669P | 2012-05-25 | 2012-05-25 | |
| US201261691083P | 2012-08-20 | 2012-08-20 | |
| US201261715907P | 2012-10-19 | 2012-10-19 | |
| US201361759520P | 2013-02-01 | 2013-02-01 | |
| US201361781629P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/042732 WO2013177559A2 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ701469A true NZ701469A (en) | 2017-06-30 |
Family
ID=49624542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701469A NZ701469A (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Country Status (24)
| Country | Link |
|---|---|
| EP (6) | EP2854814B1 (enExample) |
| JP (1) | JP6172871B2 (enExample) |
| KR (1) | KR102062640B1 (enExample) |
| CN (1) | CN104619328B (enExample) |
| AU (1) | AU2013266110C1 (enExample) |
| BR (1) | BR112014028857B1 (enExample) |
| CA (1) | CA2872260C (enExample) |
| CL (1) | CL2014003173A1 (enExample) |
| DK (5) | DK2854814T3 (enExample) |
| ES (5) | ES2665338T3 (enExample) |
| FI (1) | FI4119561T3 (enExample) |
| HK (1) | HK1250014B (enExample) |
| IL (1) | IL235868A (enExample) |
| MX (1) | MX365423B (enExample) |
| MY (1) | MY172739A (enExample) |
| NZ (1) | NZ701469A (enExample) |
| PE (1) | PE20150352A1 (enExample) |
| PH (1) | PH12014502584A1 (enExample) |
| PL (5) | PL4119561T3 (enExample) |
| PT (5) | PT2854814T (enExample) |
| RU (1) | RU2639867C2 (enExample) |
| SG (1) | SG11201407682TA (enExample) |
| WO (1) | WO2013177559A2 (enExample) |
| ZA (1) | ZA201408182B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US10047082B2 (en) * | 2013-11-25 | 2018-08-14 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
| EP3265127B1 (en) * | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
| US10610534B2 (en) * | 2015-03-30 | 2020-04-07 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| KR102876869B1 (ko) | 2015-05-18 | 2025-10-27 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| IL297201A (en) * | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| UA127409C2 (uk) | 2017-03-31 | 2023-08-16 | Корцепт Терап'Ютікс, Інк. | Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки |
| ES3043682T3 (en) | 2017-06-20 | 2025-11-25 | Corcept Therapeutics Inc | Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators |
| IL278125B (en) * | 2018-04-23 | 2022-09-01 | Corcept Therapeutics Inc | Methods for the preparation of regioselective n-alkyl triazoles |
| AU2019377864B2 (en) | 2018-11-09 | 2023-03-16 | Corcept Therapeutics Incorporated | Methods for shrinking pituitary tumors |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| IL284061B2 (en) | 2018-12-19 | 2025-02-01 | Corcept Therapeutics Inc | A preparation containing a relaxant |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| KR102832262B1 (ko) * | 2018-12-20 | 2025-07-10 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 소마토스타틴 수용체 양성 종양의 영상화 및 치료 방법 |
| CN113490496A (zh) * | 2019-02-22 | 2021-10-08 | 科赛普特治疗学股份有限公司 | 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途 |
| KR102845522B1 (ko) | 2019-10-16 | 2025-08-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 선택적 글루코코르티코이드 수용체 길항제로 암 환자의 호중구 대 림프구 비율을 정상화시키는 방법 |
| AU2020400061B2 (en) | 2019-12-11 | 2025-02-13 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| WO2021127376A1 (en) | 2019-12-21 | 2021-06-24 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| MX2022009781A (es) * | 2020-02-10 | 2022-09-09 | Corcept Therapeutics Inc | Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides. |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN116829556A (zh) * | 2021-02-03 | 2023-09-29 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| WO2024077169A1 (en) * | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| KR20250102046A (ko) | 2022-10-28 | 2025-07-04 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 다주코릴란트를 이용한 근위축성 측삭경화증의 치료 |
| US20250360125A1 (en) * | 2023-02-17 | 2025-11-27 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP4931794B2 (ja) * | 2004-03-09 | 2012-05-16 | コーセプト セラピューティクス， インコーポレイテッド | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| CA2806900A1 (en) * | 2010-08-27 | 2012-03-01 | Corcept Therapeutics, Inc. | Pyridyl-amine fused azadecalin modulators |
-
2013
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 PL PL22193438.3T patent/PL4119561T3/pl unknown
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 BR BR112014028857-7A patent/BR112014028857B1/pt active IP Right Grant
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 FI FIEP22193438.3T patent/FI4119561T3/fi active
- 2013-05-24 EP EP22193438.3A patent/EP4119561B1/en active Active
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en not_active Ceased
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active Active
- 2013-05-24 PT PT221934383T patent/PT4119561T/pt unknown
- 2013-05-24 DK DK22193438.3T patent/DK4119561T3/da active
- 2013-05-24 ES ES22193438T patent/ES2995026T3/es active Active
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 EP EP24192650.0A patent/EP4434584A3/en active Pending
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584A1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/en active IP Right Grant
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ701469A (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| EP4592275A3 (en) | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | |
| PH12015500817A1 (en) | Methylene linked quinolinyl modulators of ror-gamma-t | |
| MX340090B (es) | Analogos de spliceostatina. | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| SG10201806867VA (en) | Dll3 modulators and methods of use | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| SG10201805552PA (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| NZ700733A (en) | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| HK1216095A1 (zh) | 烟碱乙酰胆碱受体的新的正向别构调节剂 | |
| MY166463A (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX368640B (es) | Composición farmacéutica para tratar inflamación y dolor. | |
| PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
| UA72268U (ru) | Способ лечения когнитивных нарушений с помощью комплекса низкомолекулярных полипептидных фракций (препарат "кортексин") | |
| PH12015500178B1 (en) | Injectable supersaturated acetaminophen solution for spinal administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2019 BY CPA GLOBAL Effective date: 20180412 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2020 BY CPA GLOBAL Effective date: 20190411 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2021 BY CPA GLOBAL Effective date: 20200410 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2022 BY CPA GLOBAL Effective date: 20210408 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2023 BY CPA GLOBAL Effective date: 20220407 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2024 BY CPA GLOBAL Effective date: 20230406 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240411 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 MAY 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250410 |